Clinical Trials Logo

Filter by:
NCT ID: NCT05563207 Completed - Clinical trials for Acute Myeloid Leukemia

Application of Health Education Path of Traditional Chinese Medicine Nursin

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

To explore the effect of traditional Chinese medicine (TCM) health education standard path on the treatment of patients with acute myeloid leukemia (AML). A total of 60 patients with acute myeloid leukemia in Shijiazhuang Ping An Hospital were selected and divided into control group (n=30) and observation group (n=30) according to the time of admission. Both groups received the same chemotherapy, the control group received routine nursing, and the observation group received TCM health education standard path intervention. The scores of Self-rating Anxiety Scale (SAS), Self-rating Depression Scale (SDS), Spitzer Quality of Life Index (QLI), awareness of TCM health education standard path content and nursing satisfaction were compared between the two groups.

NCT ID: NCT05561855 Completed - Clinical trials for Diabetes Mellitus, Type 2

T2DM Intensity Lifestyle Intervention

Start date: October 7, 2022
Phase: N/A
Study type: Interventional

This RCT study will evaluate the effect of a lifestyle intervention on overweight or obese patients with type 2 diabetes mellitus. The primary hypothesis is that the mHealth-based intensive lifestyle intervention is sufficient to achieve weight loss and maintain glycated hemoglobin control.

NCT ID: NCT05560945 Completed - Dental Caries Clinical Trials

2-year Caries Clinical Study: Arginine Fluoride-Free Toothpastes vs. NaF Toothpaste

Start date: April 15, 2019
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the anticaries efficacy for three dentifrices (1.5% arginine in a calcium base, 8.0% arginine in a calcium base, and 0.32% sodium fluoride in a silica base) in a two-year caries clinical study

NCT ID: NCT05560360 Completed - B-cell Tumors Clinical Trials

A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects

Start date: November 4, 2022
Phase: Phase 1
Study type: Interventional

This study used a single-dose, open and fixed sequence design to compare the pharmacokinetics in healthy subjects.

NCT ID: NCT05559554 Completed - Clinical trials for Healthy Male Subjects

A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects

Start date: October 25, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetic similarity of AK104 with different manufacturing process in healthy male subjects. Another purpose is to determine safety, and immunogenicity of AK104 with different manufacturing process.

NCT ID: NCT05559138 Completed - COVID-19 Clinical Trials

Analysis of Clinical Characteristics of Hemodialysis Patients With Omicron Infection

Start date: July 1, 2022
Phase:
Study type: Observational

By collecting the clinical data of hemodialysis patients with Omicron infection in RenJi Hospital from April 7, 2022 to June 10, 2022, the clinical characteristics of this population were analyzed. And to analyze the risk factors of different clinical outcomes according to the clinical outcome of this population.

NCT ID: NCT05558618 Completed - Leadership Clinical Trials

Analysis of Personality Characteristics and Psychological Capital Factors on the Leadership of Pediatric Clinical Nurses

Start date: May 1, 2019
Phase:
Study type: Observational

Survey Methods In this study, a questionnaire on nursing leadership and influencing factors was distributed online through Wenjuanxing, an online questionnaire platform. The nursing department and the head nurse of the department where the questionnaire was to be distributed were first contacted and they agreed, and the researcher joined each department's nurses' WeChat group, distributed the questionnaire QR code, and explained the inclusion and exclusion criteria and the method of completing the questionnaire, emphasizing that the questionnaire was filled in anonymously. Nurses in each department were given 24 hours to participate in the response (the response time was around 30 minutes). Quality Control The selected nursing leadership questionnaire, EPQ-RSC scale and psychological capital questionnaire all had good reliability and validity; the inclusion and exclusion criteria and the method of completing the questionnaire were explained by the researcher to the participated nurses; questionnaires that were not filled out completely or filled out with obvious regularity, and those with L scores greater than 60 on the personality trait scale were considered invalid and were excluded; the data were checked by two people after collection. Statistical methods SPSS 22.0 was used for statistical analysis. Continuous-type data were described using the mean ± standard deviation ( ), and single-sample t-test was used for those satisfying normal distribution. Count data were described using frequency and composition ratios. Dichotomous logistic regression was used to analyze the factors influencing the leadership of pediatric clinical nurses; P<0.05 was considered a statistically significant difference when not specifically stated.

NCT ID: NCT05557955 Completed - Clinical trials for Esophageal Squamous Cell Carcinoma

Identification of Breath Biomarkers in Esophageal Cancer

EC-CRT-005
Start date: September 27, 2022
Phase:
Study type: Observational

Neoadjuvant chemoradiotherapy (CRT) followed by surgery or definitive CRT is the standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC), but the clinical outcomes are not satisfactory. Breathomics testing is a promising, non-invasive, simple method for detection and screening for ESCC. This observational study aimed to role of exhaled volatile organic compounds (VOCs) in predicting the efficacy and risk of recurrence in patients with locally advanced ESCC who received CRT.

NCT ID: NCT05557110 Completed - Clinical trials for B Acute Lymphoblastic Leukemia

Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL

Start date: September 8, 2022
Phase: Phase 2
Study type: Interventional

Blinatumomab, a CD3/CD19 bisespecific T-cell conjugative antibody, has shown high efficacy in phase I/II studies of relapsed/refractory B-lymphoblastic leukemia (B-ALL), particularly in the context of low tumor burden.Meanwhile, Blinatumomab also plays an important role in rapid and efficient clearance of MRD in patients. Therefore, its use in combination with less intensive chemotherapy for initial induction therapy in newly diagnosed patients may result in favorable response rates, greater depth of remission, and lower treatment-related toxic effects. In this study, newly diagnosed non-elderly patients with Philadelphia chromosomal negative (PH-) B-ALL were enrolled and treated with reduced-intensity chemotherapy followed by Blinatumomab as the basis of induction therapy. The clinical remission rate, MRD negative rate and treaty-related adverse reactions were evaluated in newly diagnosed non-elderly PH-B-ALL patients during induction therapy.

NCT ID: NCT05556707 Completed - COVID-19 Clinical Trials

Symptom Clusters and Risk Factors of COVID-19 Patients

Start date: May 15, 2022
Phase:
Study type: Observational [Patient Registry]

Aim and objectives: To clarify the types, composition, distribution characteristics and risk factors of symptom clusters experienced by discharged patients with COVID-19, to lay the foundation for effective symptom management. Background: Even when patients recover from COVID-19 patients, the virus can still cause many long-term effects or complications.Therefore, it is crucial to assess the symptoms and influencing factors of discharged patients with COVID-19. Design: Cross-sectional survey. Methods:The investigators used the Post Discharge Experience Assessment Questionnaire for COVID-19 Patients and the Post Discharge Symptom Experience Risk Factor Questionnaire for COVID-19 Patients were used.Stratified random sampling was used to conduct a cross-sectional survey of 384 patients in recovery from COVID-19.Exploratory factor analysis was used to determine the cluster of symptoms, and a binary logistic regression analysis was used to identify the risk factors associated with this symptom cluster.